85 related articles for article (PubMed ID: 20405848)
1. Design, synthesis, and interaction study of quinazoline-2(1H)-thione derivatives as novel potential Bcl-xL inhibitors.
Feng Y; Ding X; Chen T; Chen L; Liu F; Jia X; Luo X; Shen X; Chen K; Jiang H; Wang H; Liu H; Liu D
J Med Chem; 2010 May; 53(9):3465-79. PubMed ID: 20405848
[TBL] [Abstract][Full Text] [Related]
2. Discovery of a potent inhibitor of the antiapoptotic protein Bcl-xL from NMR and parallel synthesis.
Petros AM; Dinges J; Augeri DJ; Baumeister SA; Betebenner DA; Bures MG; Elmore SW; Hajduk PJ; Joseph MK; Landis SK; Nettesheim DG; Rosenberg SH; Shen W; Thomas S; Wang X; Zanze I; Zhang H; Fesik SW
J Med Chem; 2006 Jan; 49(2):656-63. PubMed ID: 16420051
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationship studies of ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate (HA 14-1), an antagonist for antiapoptotic Bcl-2 proteins to overcome drug resistance in cancer.
Doshi JM; Tian D; Xing C
J Med Chem; 2006 Dec; 49(26):7731-9. PubMed ID: 17181155
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship studies of phenanthridine-based Bcl-XL inhibitors.
Bernardo PH; Wan KF; Sivaraman T; Xu J; Moore FK; Hung AW; Mok HY; Yu VC; Chai CL
J Med Chem; 2008 Nov; 51(21):6699-710. PubMed ID: 18925736
[TBL] [Abstract][Full Text] [Related]
5. Quinazoline sulfonamides as dual binders of the proteins B-cell lymphoma 2 and B-cell lymphoma extra long with potent proapoptotic cell-based activity.
Sleebs BE; Czabotar PE; Fairbrother WJ; Fairlie WD; Flygare JA; Huang DC; Kersten WJ; Koehler MF; Lessene G; Lowes K; Parisot JP; Smith BJ; Smith ML; Souers AJ; Street IP; Yang H; Baell JB
J Med Chem; 2011 Mar; 54(6):1914-26. PubMed ID: 21366295
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis, and computational studies of inhibitors of Bcl-XL.
Park CM; Oie T; Petros AM; Zhang H; Nimmer PM; Henry RF; Elmore SW
J Am Chem Soc; 2006 Dec; 128(50):16206-12. PubMed ID: 17165773
[TBL] [Abstract][Full Text] [Related]
7. Fragment-based deconstruction of Bcl-xL inhibitors.
Barelier S; Pons J; Marcillat O; Lancelin JM; Krimm I
J Med Chem; 2010 Mar; 53(6):2577-88. PubMed ID: 20192224
[TBL] [Abstract][Full Text] [Related]
8. (alpha/beta+alpha)-peptide antagonists of BH3 domain/Bcl-x(L) recognition: toward general strategies for foldamer-based inhibition of protein-protein interactions.
Sadowsky JD; Fairlie WD; Hadley EB; Lee HS; Umezawa N; Nikolovska-Coleska Z; Wang S; Huang DC; Tomita Y; Gellman SH
J Am Chem Soc; 2007 Jan; 129(1):139-54. PubMed ID: 17199293
[TBL] [Abstract][Full Text] [Related]
9. Targeting the BH3 domain mediated protein-protein interaction of Bcl-xL through virtual screening.
Mukherjee P; Desai P; Zhou YD; Avery M
J Chem Inf Model; 2010 May; 50(5):906-23. PubMed ID: 20392095
[TBL] [Abstract][Full Text] [Related]
10. Discovery of potent Mcl-1/Bcl-xL dual inhibitors by using a hybridization strategy based on structural analysis of target proteins.
Tanaka Y; Aikawa K; Nishida G; Homma M; Sogabe S; Igaki S; Hayano Y; Sameshima T; Miyahisa I; Kawamoto T; Tawada M; Imai Y; Inazuka M; Cho N; Imaeda Y; Ishikawa T
J Med Chem; 2013 Dec; 56(23):9635-45. PubMed ID: 24215352
[TBL] [Abstract][Full Text] [Related]
11. De novo design, synthesis and evaluation of benzylpiperazine derivatives as highly selective binders of Mcl-1.
Ding X; Li Y; Lv L; Zhou M; Han L; Zhang Z; Ba Q; Li J; Wang H; Liu H; Wang R
ChemMedChem; 2013 Dec; 8(12):1986-2014. PubMed ID: 24124106
[TBL] [Abstract][Full Text] [Related]
12. Isosteric exchange of the acylsulfonamide moiety in Abbott's Bcl-XL protein interaction antagonist.
Dömling A; Antuch W; Beck B; Schauer-Vukasinović V
Bioorg Med Chem Lett; 2008 Jul; 18(14):4115-7. PubMed ID: 18583128
[TBL] [Abstract][Full Text] [Related]
13. Identification of lead compounds as antagonists of protein Bcl-xL with a diversity-oriented multidisciplinary approach.
Di Micco S; Vitale R; Pellecchia M; Rega MF; Riva R; Basso A; Bifulco G
J Med Chem; 2009 Dec; 52(23):7856-67. PubMed ID: 19852471
[TBL] [Abstract][Full Text] [Related]
14. 3D-QSAR pharmacophore modeling and in silico screening of new Bcl-xl inhibitors.
Almerico AM; Tutone M; Lauria A
Eur J Med Chem; 2010 Nov; 45(11):4774-82. PubMed ID: 20728251
[TBL] [Abstract][Full Text] [Related]
15. Chelerythrine and sanguinarine dock at distinct sites on BclXL that are not the classic BH3 binding cleft.
Zhang YH; Bhunia A; Wan KF; Lee MC; Chan SL; Yu VC; Mok YK
J Mol Biol; 2006 Dec; 364(3):536-49. PubMed ID: 17011577
[TBL] [Abstract][Full Text] [Related]
16. Rational design and real time, in-cell detection of the proapoptotic activity of a novel compound targeting Bcl-X(L).
Becattini B; Kitada S; Leone M; Monosov E; Chandler S; Zhai D; Kipps TJ; Reed JC; Pellecchia M
Chem Biol; 2004 Mar; 11(3):389-95. PubMed ID: 15123268
[TBL] [Abstract][Full Text] [Related]
17. Aven, a novel inhibitor of caspase activation, binds Bcl-xL and Apaf-1.
Chau BN; Cheng EH; Kerr DA; Hardwick JM
Mol Cell; 2000 Jul; 6(1):31-40. PubMed ID: 10949025
[TBL] [Abstract][Full Text] [Related]
18. Rational design of new class of BH3-mimetics as inhibitors of the Bcl-xL protein.
Pinto M; Orzaez Mdel M; Delgado-Soler L; Perez JJ; Rubio-Martinez J
J Chem Inf Model; 2011 Jun; 51(6):1249-58. PubMed ID: 21528891
[TBL] [Abstract][Full Text] [Related]
19. Terephthalamide derivatives as mimetics of helical peptides: disruption of the Bcl-x(L)/Bak interaction.
Yin H; Lee GI; Sedey KA; Rodriguez JM; Wang HG; Sebti SM; Hamilton AD
J Am Chem Soc; 2005 Apr; 127(15):5463-8. PubMed ID: 15826183
[TBL] [Abstract][Full Text] [Related]
20. A new assay for the discovery of Bcl-XL inhibitors.
Pisoni C; Cimoli G; Resconi A; Losi D; Lorenzetti R; Parodi S; Carrano L
Farmaco; 2005; 60(11-12):938-43. PubMed ID: 16054143
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
